Spring may finally be here for multinationals looking for a smoother development path for their new drugs in China.
Just days after the head of the country’s drug review and approval agency expressed publicly a willingness to welcome more...
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to bolster multinationals’ interest and activity in China, and to quicken the pace of launches to potentially overcome the country’s “drug lag”.
Spring may finally be here for multinationals looking for a smoother development path for their new drugs in China.
Just days after the head of the country’s drug review and approval agency expressed publicly a willingness to welcome more...